PD-L1 marks a subset of melanomas with a shorter overall survival and distinct genetic and morphological characteristics

Annals of Oncology

Volumn 25, Issue 12, 2014, Pages 2433-2442

  Massi, D ^a   Brusa, D ^b   Merelli, B ^c   Ciano, M ^b   Audrito, V ^b,d   Serra, S ^b,d   Buonincontri, R ^b,d   Baroni, G ^a   Nassini, R ^a   Minocci, D ^a   Cattaneo, L ^c   Tamborini, E ^e   Carobbio, A ^c   Rulli, E ^f   Deaglio, S ^b,d   Mandala M ^c  

^a UNIVERSITY OF FLORENCE   (Italy)

^b HuGeF Human Genetics Foundation Torino   (Italy)

^c PAPA GIOVANNI XXIII HOSPITAL   (Italy)

^d UNIVERSITY OF TURIN   (Italy)

^e NATIONAL CANCER INSTITUTE   (Italy)

^f MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

Metastatic melanoma; PD L1; Prognostic markers

Indexed keywords

ALPHA1 INTEGRIN; ALPHA3 INTEGRIN; ALPHA5 INTEGRIN; B RAF KINASE; CAVEOLIN 1; CD56 ANTIGEN; CD74 ANTIGEN; DABRAFENIB; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MESSENGER RNA; PROGRAMMED DEATH 1 LIGAND 1; VEMURAFENIB; CD274 PROTEIN, HUMAN; TUMOR MARKER;

A375 CELL LINE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER MORTALITY; CANCER PROGNOSIS; CELL INVASION; CELL MIGRATION; CONTROLLED STUDY; DISEASE FREE SURVIVAL; GENE EXPRESSION PROFILING; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; METASTATIC MELANOMA; MOUSE; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR GROWTH; TUMOR XENOGRAFT; UPREGULATION; GENETICS; MELANOMA; METABOLISM; METASTASIS; PATHOLOGY; SURVIVAL; TUMOR INVASION;

ANTIGENS, CD274; HUMANS; MELANOMA; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84927613720     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdu452     Document Type: Article

References (20)

1. Garbe C, Peris K, Hauschild A et al. Diagnosis and treatment of melanoma: European consensus-based interdisciplinary guideline. Eur J Cancer 2010; 46: 270-283.
2. Flaherty KT, Puzanov I, Kim KB et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010; 363: 809-819.
3. Hauschild A, Grob JJ, Demidov LV et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 2012; 380: 358-365.
4. Salama AK, Flaherty KT. BRAF in melanoma: current strategies and future directions. Clin Cancer Res 2013; 19: 4326-4334.
5. Topalian SL, Hodi FS, Brahmer JR et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366: 2443-2454.
6. Hamid O, Robert C, Daud A et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 2013; 369: 134-144.
7. Brahmer JR, Tykodi SS, Chow LQ et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012; 366: 2455-2465.
8. Crawford A, Wherry EJ. Inhibitory receptors: whose side are they on? Nat Immunol 2007; 8: 1201-1203.
9. Yamazaki T, Akiba H, Iwai H et al. Expression of programmed death 1 ligands by murine T cells and APC. J Immunol 2002; 169: 5538-5545.
10. Thompson RH, Gillett MD, Cheville JC et al. Costimulatory B7-H1 in renal cell carcinoma patients: indicator of tumor aggressiveness and potential therapeutic target. Proc Natl Acad Sci USA 2004; 101: 17174-9.
11. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012; 12: 252-264.
12. Taube JM, Anders RA, Young GD et al. Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med 2012; 4: 127-137.
13. Merelli B, Massi D, Cattaneo L, Mandalà M. Targeting the PD1/PD-L1 axis in melanoma: biological rationale, clinical challenges and opportunities. Crit Rev Oncol Hematol 2014; 89: 140-165.
14. Gadiot J, Hooijkaas AI, Kaiser AD et al. Overall survival and PD-L1 expression in metastasized malignant melanoma. Cancer 2011; 117: 2192-2201.
15. Hino R, Kabashima K, Kato Y et al. Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma. Cancer 2010; 116: 1757-1766.
16. Dong H, Strome SE, Salomao DR et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 2002; 8: 793-800.
17. Lipson EJ, Taube JM, Chen L et al. Anti-PD-1 and anti-B7-H1/PD-L1 monoclonal antibodies. In Gajewski TF, Hodi FS (eds), Targeted Therapeutics in Melanoma. Springer Science + Business Media, New York 2012; 291-306.
18. Atefi M, Avramis E, Lassen A et al. Effects of MAPK and PI3K pathways on PD-L1 expression in melanoma. Clin Cancer Res 2014; 20: 3446-3457.
19. Abiko K, Mandai M, Hamanishi J et al. PD-L1 on tumor cells is induced in ascites and promotes peritoneal dissemination of ovarian cancer through CTL dysfunction. Clin Cancer Res 2013; 19: 1363-1374.
20. Wang L, Liu H, Chen X et al. Immune sculpting of norepinephrine on MHC-I, B7-1, IDO and B7-H1 expression and regulation of proliferation and invasion in pancreatic carcinoma cells. PLoS One 2012; 7: e45491.